Conatus Pharmaceuticals (CNAT) – Trader Talk
-
Conatus (CNAT) falls 45% after announcing emricasan did not have the desired effect in earlier-stage NASH fibrosis patients
-
Russell Announces 3000 Index Preliminary Additions and Deletions
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Back to CNAT Stock Lookup